Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
BIOC-11 is under development for the treatment of bronchiectasis caused by Pseudomonas aeruginosa and cystic fibrosis. This candidate is formulated as an isotonic, buffered aqueous solution for oral ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...
In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Changing Futures, a nonprofit dedicated to advancing cystic fibrosis (CF) research, will hold a polar plunge at noon New Year ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback